Phathom Pharmaceuticals
PHAT
110 hedge funds and large institutions have $453M invested in Phathom Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 7 closing their positions.
395% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $326K
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 24
7% more funds holding
Funds holding: 103 → 110 (+7)
1.11% less ownership
Funds ownership: 78.15% → 77.04% (-1.1%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
26% less capital invested
Capital invested by funds: $613M → $453M (-$160M)
Top Buyers
| 1 |
BlackRock
New York
|
+$5.97M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.55M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$3.42M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$3.3M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.88M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$9.39M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.56M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.58M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.86M |
| 5 |
6CM
683 Capital Management
New York
|
-$2.57M |
PHAT Hedge Fund Activity: Q3 2023 in Review
110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2023, worth a combined $453M — down 26% from $613M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PHAT positions and 7 closed out — a net gain of 8 holders — while 48 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $5.97M. The largest seller was Deerfield Management, exiting entirely with an estimated $9.39M sold.
- 110 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2023, up from 103 in Q2 2023.
- Funds reported $453M of Phathom Pharmaceuticals stock for Q3 2023, down 26% quarter-over-quarter.
- 15 funds opened new Phathom Pharmaceuticals positions in Q3 2023 and 7 closed out, a net change of +8 holders.
- The largest Phathom Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $5.97M added.
- The largest Phathom Pharmaceuticals seller in Q3 2023 was Deerfield Management, an estimated $9.39M sold.
Based on aggregated 13F filings for Q3 2023.